Johnson & Johnson is warning doctors not to start new patients on its cancer drug Doxil due to a supply shortage—the latest in a series of shortages from various drug makers that have hamstrung health-care providers. J&J's Janssen unit sent a letter to doctors Tuesday saying a contract manufacturer is experiencing production delays for Doxil, which is approved to treat ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
